Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

NCT07089719 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Dyspnea Caused by 2019-nCoV

Interventions

DRUG: Bevacizumab Injection

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]
[object Object]